Literature DB >> 22855607

A major determinant of the immunogenicity of factor VIII in a murine model is independent of its procoagulant function.

Shannon L Meeks1, Courtney L Cox, John F Healey, Ernest T Parker, Bhavya S Doshi, Bagirath Gangadharan, Rachel T Barrow, Pete Lollar.   

Abstract

A main complication of treatment of patients with hemophilia A is the development of anti-factor VIII (fVIII) antibodies. The immunogenicity of fVIII potentially is a function of its procoagulant activity, which may result in danger signals that drive the immune response. Alternatively, intrinsic structural elements in fVIII may be particularly immunogenic. Finally, VWF, the carrier protein for fVIII in plasma, may play a role in immune recognition. We compared the immunogenicity of wild-type (wt) B domain-deleted fVIII and 2 inactive fVIII molecules, R372A/R1689A fVIII and V634M fVIII in fVIII(-/-) and fVIII(-/-)/VWF(-/-) mice. R372A/R1689A fVIII lacks proteolytic recognition sites and is not released from VWF. In contrast, V634M fVIII undergoes proteolytic cleavage and dissociation from VWF. No significant difference was observed in the immunogenicity of wt fVIII and V634M fVIII. R372A/R1689A fVIII was slightly less immunogenic in a subset of immunization regimens tested. High doses of wt fVIII were required to produce an immune response in fVIII(-/-)/VWF(-/-) mice. Our results indicate that a main component of the immune response to fVIII is independent of its procoagulant function, is both positively and negatively affected by its association with VWF, and may involve intrinsic elements of fVIII structure.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22855607      PMCID: PMC3448263          DOI: 10.1182/blood-2012-02-412361

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  47 in total

1.  Antigen stored in dendritic cells after macropinocytosis is released unprocessed from late endosomes to target B cells.

Authors:  Delphine Le Roux; Agnès Le Bon; Audrey Dumas; Kahina Taleb; Martin Sachse; Romain Sikora; Marion Julithe; Alexandre Benmerah; Georges Bismuth; Florence Niedergang
Journal:  Blood       Date:  2011-11-02       Impact factor: 22.113

2.  C1 domain residues Lys 2092 and Phe 2093 are of major importance for the endocytic uptake of coagulation factor VIII.

Authors:  Henriët Meems; Maartje van den Biggelaar; Mariska Rondaij; Carmen van der Zwaan; Koen Mertens; Alexander B Meijer
Journal:  Int J Biochem Cell Biol       Date:  2011-04-08       Impact factor: 5.085

Review 3.  Clearance mechanisms of von Willebrand factor and factor VIII.

Authors:  P J Lenting; C J M VAN Schooten; C V Denis
Journal:  J Thromb Haemost       Date:  2007-04-07       Impact factor: 5.824

4.  Uptake of blood coagulation factor VIII by dendritic cells is mediated via its C1 domain.

Authors:  Eszter Herczenik; Simon D van Haren; Aleksandra Wroblewska; Paul Kaijen; Maartje van den Biggelaar; Alexander B Meijer; Luisa Martinez-Pomares; Anja ten Brinke; Jan Voorberg
Journal:  J Allergy Clin Immunol       Date:  2011-10-01       Impact factor: 10.793

5.  Factor VIII A3 domain substitution N1922S results in hemophilia A due to domain-specific misfolding and hyposecretion of functional protein.

Authors:  Ryan J Summers; Shannon L Meeks; John F Healey; Harrison C Brown; Ernest T Parker; Christine L Kempton; Christopher B Doering; Pete Lollar
Journal:  Blood       Date:  2011-01-07       Impact factor: 22.113

6.  Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment.

Authors:  Baisong Mei; Clark Pan; Haiyan Jiang; Hendri Tjandra; Jonathan Strauss; Yaoqi Chen; Tongyao Liu; Xin Zhang; Joanne Severs; Jim Newgren; Jianmin Chen; Jian-Ming Gu; Babu Subramanyam; Michael A Fournel; Glenn F Pierce; John E Murphy
Journal:  Blood       Date:  2010-03-01       Impact factor: 22.113

7.  Splenic marginal zone antigen-presenting cells are critical for the primary allo-immune response to therapeutic factor VIII in hemophilia A.

Authors:  A Navarrete; S Dasgupta; S Delignat; G Caligiuri; O D Christophe; J Bayry; A Nicoletti; S V Kaveri; S Lacroix-Desmazes
Journal:  J Thromb Haemost       Date:  2009-08-11       Impact factor: 5.824

8.  A role for thrombin in the initiation of the immune response to therapeutic factor VIII.

Authors:  Jonathan Skupsky; Ai-Hong Zhang; Yan Su; David W Scott
Journal:  Blood       Date:  2009-09-30       Impact factor: 22.113

9.  Macrophages contribute to the cellular uptake of von Willebrand factor and factor VIII in vivo.

Authors:  Carina J van Schooten; Shirin Shahbazi; Evelyn Groot; Beatrijs D Oortwijn; H Marijke van den Berg; Cécile V Denis; Peter J Lenting
Journal:  Blood       Date:  2008-06-16       Impact factor: 22.113

10.  Antihuman factor VIII C2 domain antibodies in hemophilia A mice recognize a functionally complex continuous spectrum of epitopes dominated by inhibitors of factor VIII activation.

Authors:  Shannon L Meeks; John F Healey; Ernest T Parker; Rachel T Barrow; Pete Lollar
Journal:  Blood       Date:  2007-09-11       Impact factor: 22.113

View more
  23 in total

1.  Role of factor VIII-binding capacity of endogenous von Willebrand factor in the development of factor VIII inhibitors in patients with severe hemophilia A.

Authors:  Yohann Repessé; Catherine Costa; Roberta Palla; Elika Farrokhi Moshai; Annie Borel-Derlon; Roseline D'Oiron; Chantal Rothschild; Amal El-Beshlawy; Mohsen Elalfy; Vijay Ramanan; Peyman Eshghi; Johannes Oldenburg; Anna Pavlova; Frits R Rosendaal; Flora Peyvandi; Srinivas V Kaveri; Sébastien Lacroix-Desmazes
Journal:  Haematologica       Date:  2019-01-31       Impact factor: 9.941

Review 2.  Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A.

Authors:  Steven W Pipe; Robert R Montgomery; Kathleen P Pratt; Peter J Lenting; David Lillicrap
Journal:  Blood       Date:  2016-09-01       Impact factor: 22.113

3.  Anti-C1 domain antibodies that accelerate factor VIII clearance contribute to antibody pathogenicity in a murine hemophilia A model.

Authors:  G Batsuli; J Ito; R Mercer; W H Baldwin; C Cox; E T Parker; J F Healey; P Lollar; S L Meeks
Journal:  J Thromb Haemost       Date:  2018-08-13       Impact factor: 5.824

4.  Removal of single-site N-linked glycans on factor VIII alters binding of domain-specific monoclonal antibodies.

Authors:  Jasmine Ito; Wallace Hunter Baldwin; Courtney Cox; John F Healey; Ernest T Parker; Emily R Legan; Renhao Li; Surinder Gill; Glaivy Batsuli
Journal:  J Thromb Haemost       Date:  2021-12-17       Impact factor: 5.824

5.  Development of inhibitory antibodies to therapeutic factor VIII in severe hemophilia A is associated with microsatellite polymorphisms in the HMOX1 promoter.

Authors:  Yohann Repessé; Ivan Peyron; Jordan D Dimitrov; Suryasarathi Dasgupta; Elika Farrokhi Moshai; Catherine Costa; Annie Borel-Derlon; Benoit Guillet; Roseline D'Oiron; Achille Aouba; Chantal Rothschild; Johannes Oldenburg; Anna Pavlova; Srinivas V Kaveri; Sébastien Lacroix-Desmazes
Journal:  Haematologica       Date:  2013-05-28       Impact factor: 9.941

6.  Marginal zone B cells are critical to factor VIII inhibitor formation in mice with hemophilia A.

Authors:  Patricia E Zerra; Courtney Cox; W Hunter Baldwin; Seema R Patel; Connie M Arthur; Pete Lollar; Shannon L Meeks; Sean R Stowell
Journal:  Blood       Date:  2017-10-04       Impact factor: 22.113

7.  High-affinity, noninhibitory pathogenic C1 domain antibodies are present in patients with hemophilia A and inhibitors.

Authors:  Glaivy Batsuli; Wei Deng; John F Healey; Ernest T Parker; W Hunter Baldwin; Courtney Cox; Brenda Nguyen; Joerg Kahle; Christoph Königs; Renhao Li; Pete Lollar; Shannon L Meeks
Journal:  Blood       Date:  2016-07-05       Impact factor: 22.113

8.  Characterization of a genetically engineered mouse model of hemophilia A with complete deletion of the F8 gene.

Authors:  B N Chao; W H Baldwin; J F Healey; E T Parker; K Shafer-Weaver; C Cox; P Jiang; C Kanellopoulou; P Lollar; S L Meeks; M J Lenardo
Journal:  J Thromb Haemost       Date:  2016-01-08       Impact factor: 5.824

9.  Population-specific design of de-immunized protein biotherapeutics.

Authors:  Benjamin Schubert; Charlotta Schärfe; Pierre Dönnes; Thomas Hopf; Debora Marks; Oliver Kohlbacher
Journal:  PLoS Comput Biol       Date:  2018-03-02       Impact factor: 4.475

10.  On the versatility of von Willebrand factor.

Authors:  Antoine Rauch; Nikolett Wohner; Olivier D Christophe; Cécile V Denis; Sophie Susen; Peter J Lenting
Journal:  Mediterr J Hematol Infect Dis       Date:  2013-07-10       Impact factor: 2.576

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.